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Abstract
Posttranscriptional modifications are critical for structure and function of tRNAs. Wybutosine (yW) and its derivatives are
hyper-modified guanosines found at the position 37 of eukaryotic and archaeal tRNA
Phe. TYW2 is an enzyme that catalyzes
a-amino-a-carboxypropyl transfer activity at the third step of yW biogenesis. Using complementation of a DTYW2 strain, we
demonstrate here that human TYW2 (hTYW2) is active in yeast and can synthesize the yW of yeast tRNA
Phe. Structure-
guided analysis identified several conserved residues in hTYW2 that interact with S-adenosyl-methionine (AdoMet), and
mutation studies revealed that K225 and E265 are critical residues for the enzymatic activity. We previously reported that
the human TYW2 is overexpressed in breast cancer. However, no difference in the tRNA
Phe modification status was observed
in either normal mouse tissue or a mouse tumor model that overexpresses Tyw2, indicating that hTYW2 may have a role in
tumorigenesis unrelated to yW biogenesis.
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Introduction
Though over 100 modified bases have been characterized in
tRNAs, the biosynthetic pathways leading to many modifications
in mammalian tRNAs are not well understood. Wybutosine (yW)
is one of the highly modified bases, located at position 37 in
tRNA
Phe, and its biosynthetic pathway, including characterization
of four novel TYW enzymes (tRNA-yW synthesizing proteins), has
now been elucidated in yeast [1]. In yeast, the biosynthesis of yW
consists of a six-step process involving five different enzymes:
TRM5, TYW1, TYW2, TYW3, TYW4 (Figure 1A) [1], and each
step is mediated by the binding of S-adenosyl-methoinine
(AdoMet). In the first step of the reaction, the G37 base of
tRNA
Phe is methylated by TRM5, a methyltransferase, using
AdoMet as the methyl group donor. Step two is the formation of
a tricyclic ring catalyzed by TYW1, an iron-cluster protein. Step
three is mediated by a transferase, TYW2, which transfers the
bulky a-amino-a-carboxypropyl (acp) group from AdoMet to the
side-chain at C-7 position of yW-187 to produce yW-86. Step four
is the methylation of the N-4 position of yW-86, by TYW3, to
yield yW-72. Steps five and six are mediated by TYW4,
a carboxymethyltransferase. Methylation of the a-carboxy group
of yW-72 forms yW-58, then methoxycarbonylation of the a-
amino group of yW-58 produces the fully modified yW base. The
human gene, initially known as TRMT12 and TRM12, was
renamed TYW2 based on its sequence homology to the yeast
TYW2 gene. We wanted to explore whether the human TYW2
provides a similar enzymatic activity to its yeast counterpart in yW
biosynthesis.
The yW base in yeast tRNA
Phe was initially described nearly
four decades ago [2], and is found exclusively in tRNA
Phe from
Eukarya and Archaea [3]. The guanosine (G) at position 37,
immediately 39 to the anticodon in tRNA
Phe, undergoes post-
transcriptional modification to yW. The yW base stabilizes the
codon-anticodon interaction and functions to maintain the
correct reading frame [4]. Early on, it was observed that
tRNA
Phe from rat and mouse tumors, unlike normal tissues, did
not carry the fully modified yW base [5]. Later, it was
determined that the under-modification of the yW base in
tRNA
Phe could cause –1 frameshifting during translation [6].
Previously, we demonstrated that human TYW2 (hTYW2) was
amplified and overexpressed in breast cancer. High-density BAC
arrays revealed amplification of an ,1 Mb region on chromo-
some 8 in several breast cancer cell lines, and hTYW2, located
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all the cell lines. RNA from 30 breast tumors was examined and
hTYW2 was found to be expressed .2 fold in 87% of the tumors
[7]. Therefore, it was of interest to evaluate whether over-
expression of the hTYW2 disrupted the wybutosine pathway in
the mammary tumor cells.
In this study, we identify a mouse mammary tumor model that
overexpresses Tyw2 and explore whether the biosynthesis of yW
base is compromised in tRNA
Phe from the tumors. We demon-
strate in an in vivo system that the biological function of human
TYW2 in the posttranscriptional modification of tRNA
phe,i s
similar to that of its yeast homolog. Additionally, based on our
observation that human TYW2 catalyzes the transfer of an acp
group from AdoMet, implying a crucial role in the biosynthesis of
yW, we use a homology model to predict the critical resides for
enzymatic activity and follow up with mutagenesis studies to
provide experimental verification.
Figure 1. Human TYW2 has the same enzyme activity as its yeast counterpart in Wybutosine (yW) biosynthesis. (A) Wybutosine (yW)
biosynthetic pathway in yeast. The yW base is located adjacent to the anticodon in tRNA
Phe. The pathway for yW biosynthesis in yeast has been
described earlier [1]. (B) LC/MS analysis of nuclease P1 digested tRNA-Phe obtained from wild type (WT), the TYW2 deletion strain (DTYW2), and the
deletion strain transformed with pYES2/hTYW2 (pYES2/hTYW2 in DTYW2). The panels show mass chromatograms detecting MH+ (m/z 838) of yWpA,
BH2+ (m/z 377) of yW, MH+ (m/z 651) of yW-187pA, MH+ (m/z 322) of yW-187 and BH2+ (m/z 190) of yW-187, respectively.
doi:10.1371/journal.pone.0039297.g001
Human TYW2 in Biosynthesis of yW Base in tRNA-Phe
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39297Materials and Methods
Mouse Mammary Tissue
Normal mouse mammary tissue was obtained from pregnant
FVB/N mice at about 18 days of gestation. Mammary tumor
tissue was obtained from mice heterozygous for the C3 (1)/SV40-
T/t-antigen [C3 (1)/Tag] transgene in the FVB/N background as
previously described [8]. Mice were euthanized at about 5 months
of age when tumors were 1–2 cm in diameter. Mammary tumors
were also extracted from MMTV-Her2/neu [9] and MMTV-
PymT [10] transgenic mice when they developed generally
between 5 and 7 months of age.
cDNA Preparation and Quantitative PCR
Total RNA was extracted with phenol-chloroform (TRIzol
reagent, Invitrogen), treated with DNase, and the quality of the
RNA was assessed using the 2100 Bioanalyzer (Agilent Technol-
ogies, Cedar Creek, TX). cDNA was prepared using the
SuperScript First strand Synthesis kit (Invitrogen). The 2-DDCt
method was used to determine the Tyw12 gene expression and
represented as fold changes relative to that of the normal mouse
mammary sample [11]. ß2M gene expression served as the
internal reference and quantitative PCR (RT-qPCR), was
performed using the Fast SYBR Green kit (Applied Biosystems,
Foster City, CA). Mouse Tyw2 primers: GTGCCAACT-
TAGGGCTTGAG and CCTCGGGTAATGAGAAACCA, and
ßB2M primers: GATCATATGCCAAACCCTCTG and
TGGGGGTGAGAATTGCTAAG.
Plasmids
The human hTYW2 expression plasmid was obtained from
Origene (Rockville, MD) (cat# TC113870). The coding region of
hTYW2 was PCR amplified and cloned into the yeast (pYES2)
vector by standard cloning techniques, and the construct was
verified by sequencing.
Yeast Complementation Test
Saccharomyces cerevisiae DTYW2 gene deletion strain was obtained
from EUROSCARF: the Y10571 strain (BY4742 (Mata; his3D1;
leu2D0; lys2D0; ura3D0), YML005w::kanmx4) was transformed by
pYES2/hTYW2. The transformant was cultivated overnight in
SC-ura/glucose media (0.67% yeast nitrogen base without amino
acids, 0.5% casamino acid, and 2% glucose supplemented by
auxotrophic nutrients as specified without uracil), and then diluted
into SC-ura/raffinose media (0.67% yeast nitrogen base without
amino acids, 0.5% casamino acid, and 2% raffinose, supplemented
by auxotrophic nutrients as specified without uracil) at a starting
OD600 < 0.4. Protein was induced by culturing in YPG media
(2% peptone, 1% yeast extract and 2% galactose) for 20 hours.
Total tRNA from each strain was extracted, and their modified
nucleosides were analyzed by LC/MS.
Mass Spectroscopy
Total tRNA was isolated from total RNA from each strain on
10% polyacrylamide gels containing 7 M urea. To analyze RNA
nucleosides, 20 mg of total tRNA was digested to nucleosides with
nuclease P1 (Yamasa, Salem, OR) and bacterial alkaline
phosphatase derived from Escherichia coli strain C75 (BAP.C75),
(Takara Mountain View, CA) for 3 h at 37 ˚C, and analyzed by
LC/MS using ion trap mass spectrometry as described previously
[1]. Nucleosides were separated by an ODS reverse-phase column
(Intersil ODS3 5 mm, 2.16250 mm, GL Science) using an
HP1100 liquid chromatography system (Agilent Technologies,
Palo Alto, CA). The solvent consisted of 0.1% acetonitrile in
5m MN H 4OAc (pH 5.3) (Solvent A) and 60% acetonitrile in
H2O (Solvent B) in the following gradients: 1–35% B in 0–35 min,
35–99% B in 35–40 min, 99% B in 40–45 min, 99–1% B in 50–
50.1 min and 1% B in 50.1–60 min. The chromatographic
effluent was directly conducted to the electrospray ionization
(ESI) source to ionize the separated nucleosides, which were
analyzed on a LCQ DUO ion trap mass spectrometer (Thermo
Fisher Scientific, Pittsburgh, PA). The mass spectrometer was
operated with a spray voltage of 5 kV and a capillary temperature
of 245 ˚C. The sheath gas flow rate was 95 arb, auxiliary gas flow
rate was 5 arb. Positive ions were scanned over an m/z range of
103 to 900.
tRNA Extraction, Labeling, and Fractionation
Total tRNA was extracted from 1 gram of either normal or
tumor mouse mammary tissue [12], aminoacylated with [
3H]-
phenylalanine and 19 unlabeled amino acids under limiting tRNA
conditions in the presence of rabbit reticulocyte synthetases [13].
The resulting aminoacylated tRNA was fractionated on a RPC-5
column [14] as described previously [13]. Total calf liver tRNA
was purchased from Sigma (St. Louis, MO) and aminoacylated
with [
14C]-phenylalanine as described above and co-chromato-
graphed with [
3H]-phenylalanine labeled normal or tumor mouse
tRNA.
Northern Blot Analysis
Total tRNA was quantified, and 0.8 mg of each sample was run
on a 15% TBE-Urea gel (Invitrogen, Carlsbad, CA), and
transblotted onto a nylon membrane. The membrane was
hybridized with a
32P-59-end-labeled oligonucleotide that was
complementary to the sequence 59- TGCCGAAACCCGG-
GATCGAACCAGGGAC-39 at the 39 end of tRNA
Phe and the
Northern blot was analyzed using a PhosphorImager. The blot
was stripped and probed with a
32P-59-end-labeled oligonucleotide
that was complementary to the 20 nucleotides at the 39 end of
tRNA
Ser1 that was used as an internal control, Ser [15].
Bioinformatics and Structural Analysis
The protein information was obtained from the UniProt
database (www.uniprot.org). Domain information was obtained
from the Pfam database (http://pfam.sanger.ac.uk/). The struc-
tural information for the available homologous structures was
obtained from the Protein Data Bank, PDB (www.rcsb.org).
Topological information was obtained from PDBSum (http://
www.ebi.ac.uk/pdbsum/) database [16]. Structure-guided align-
ment of the homologous sequences and structures was done using
Cn3d tool implemented within the CDTree (http://www.ncbi.
nlm.nih.gov/Structure/cdtree/cdtree.shtml) tool [17]. Single-link-
age clustering was done using the CDTree tool. Protein family
classification was done using the PIRSF classification system
(pir.georgetown.edu). Classification of protein sequences or
structures into families that reflect their ancestry is valuable in
providing clues about a protein’s function. The PIRSF system built
as a hierarchical structure was designed to provide a solid
framework that enables functional annotation at various levels of
hierarchy. This system clusters full-length proteins into homeo-
morphic families [18]. Proteins are assigned to the same PIRSF
only if they share end-to-end similarity including similar domain
architectures. The homologous sequences used to compute the
tree were based on PIRSF family memberships. Homology
modeling was done using the Swiss-pdb viewer [19]. The model
was refined and minimized using the GROMOS986 potentials
implemented in Swiss-pdb viewer.
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Human TYW2 can substitute for the yeast enzyme in the
biosynthesis of yW base in tRNA
Phe Sequence analysis shows
that the human TYW2 protein (448 amino acids) shares 35%
identity with the yeast TYW2 protein (462 amino acids), and the
homology primarily resides in its transferase domain (amino acids
118–336). The N-terminal 117 residues and the C-terminal 112
residues of hTYW2 do not resemble any known domain.
However, the former shows homology to TYW2 sequences from
mammals and the latter is conserved even in sequences from
plants and protozoans. To determine whether hTYW2 can
replace the function of the yeast TYW2 in vivo, a yeast
complementation test was performed. The hTYW2 gene was
cloned into the yeast vector pYES2, and the DTYW2 deletion
strain, Y10571, was transformed by pYES2/hTYW2. Total
tRNA was extracted from wild type, deletion and transformed
yeast strains, and their modified nucleosides were analyzed by
LC/MS (Figure 1B). Wybutosine (yW) was detected as the
proton adduct form (MH+) of the dinucleotide yWpA (m/z 838,
RT 46.8 min) and a peak for the protonated base fragment
(BH2+) of yW (m/z 377) in the wild type strain (left panel). These
peaks are absent in the DTYW2 strain (middle panel), but are
detected when the deletion strain is transformed with pYES2/
hTYW2 (right panel). Also, the intermediate yW-187pA (m/z
651, RT 34.5 min) shown in the middle panel is no longer
present in the right panel indicating that yW-187pA has been
converted to the fully modified yW base. This confirmed that the
human hTYW2 protein catalyzes the third step in the bio-
synthesis of wybutosine and thus established a biological function
of this protein in mammalian cells.
Model Building and Sequence Analysis to Identify the
Amino Acid Residues that are Critical for Enzymatic
Activity in hTYW2
In order to identify critical and functionally important residues
in hTYW2, analysis at various sequence and structure levels was
carried out. Based on sequence analysis, the query protein
Q53H54 (TYW2_HUMAN) is an AdoMet-dependent transferase
with substrate specificity for tRNAs. The yeast and archaeal
homologs of TYW2 have been shown to be transferases that
transfer a a-amino-a-carboxypropyl group (acp) from AdoMet
instead of a methyl group which is typical of AdoMet-dependent
transferases [1,20]. Domain analysis was carried out using the
Pfam database [21], and hTYW2 belongs to PF02475 Met-10+
like-protein family. This family contains proteins involved in
methyltransferase activity and proteins involved in methionine
biosynthesis. The members of this family display about 40
different domain architectures with majority containing only the
Met-10+ domain. Residues 118–336 of hTYW2 contain the
transferase domain. We generated a homology model of hTYW2
based on the crystal structure of protein PH0793 (TYW2) from
Pyrococcus horikoshii (PDB-ID: initially 2FRN, and then 3K6R) in
order to locate important residues in the AdoMet binding pocket.
Since the sequence homology between the archaeal TYW2 and
hTYW2 was only 35%, the model was generated so not to miss
any features specific to hTYW2. We re-computed the model
using the crystal structure of the same (Pyrococcus horikoshii TYW2)
protein in complex with AdoMet (PDB-ID: 3A25) [20], after it
became available. The hTYW2 protein models based on the
unbound and the AdoMet-bound Pyrococcus horikoshii TYW2
crystal structures were consistent with each other.
Analysis of 300 or so AdoMet bound structures (data not
shown) shows that structures of methyltransferases belonging to
Class I, in general, display two major strand arrangements
6754123 and 3214576 (with strand 7 anti-parallel to the
remaining strands). The hTYW2 belongs to AdoMet-dependent
methyltransferase SCOP (http://scop.mrc-lmb.cam.ac.uk/scop)
fold with a topology consistent with Class I methyltransferases.
The arrangement of beta strands is in the order 6754123 with
strand 7 anti-parallel to rest of the strands as is typically seen in
this fold. It belongs to the class of alpha/beta proteins as per
SCOP classifications [22].
Family classification analysis using PIR classification system
shows that hTYW2 belongs to PIRSF038667 homeomorphic
family consisting specifically of mammals, while the archaeal and
yeast homologs belong to PIRSF006525 and PIRSF038972
respectively. The PIRSF classification of proteins is based on
end-to-end similarity and similar domain architectures. The
average lengths of the members belonging to PIRSF038667,
PIRSF06525 and PIRSF038972 are 437, 325 and 430 amino
acids respectively. While the mammalian and yeast proteins have
similar lengths, their sequence identity is only about 35%. Yeast
TYW2 has diverged far away from its archaeal homologs with
sequence identities of only 23%. It is interesting that although the
sequences have diverged and fall into distinct families, the proteins
have highly conserved structure and function. Single-linkage
clustering analysis shows three distinct branches separating
archaeal, fungal, and mammalian TYW2 proteins (Figure S1,
Table S1).
In order to identify key conserved residues in the AdoMet
binding pocket for mutagenesis studies, a structure-guided
alignment of structures and sequences from members of the
three PIRSFs was done using Cn3d/CDtree tool. Since the
conservation is only at the structural level, a structure-guided
alignment rather than a traditional sequence alignment is more
meaningful. An alignment (Figure S2, Table S1) was constructed
with all the representative members from the three PIRSFs,
a total of 49 sequences. Another alignment was constructed from
18 members within this set that have been annotated/reviewed
in the UniProt Swiss-Prot section of the UniProtKB database
and is presented in Figure 2. Based on the alignment and the
evaluation of other Class I structures (data not presented),
candidates that make H-bond interactions with the AdoMet
moiety were chosen for mutagenesis experiments: K225, Y242
(Y242 displays a stacking interaction with the adenosine moiety),
F248, E265, and D293.
Mutagenesis of the Critical Residues in hTYW2 and
Evaluation of its Consequence on yW Biosynthesis
We chose to evaluate the role that each of the five candidate
amino acids play in yW biosynthesis by converting each to alanine:
K225A, Y242A, F248A, E265A, and D293A. We generated the
five mutant hTYW2 constructs in the yeast vector, pYES2, and
evaluated their enzymatic activity in yeast by determining their
ability to substitute the yeast homolog. We found mutations
K225A and E265A eliminated the enzyme activity whereas
mutants Y242A, F248A and D293A retained the enzyme activity,
showing that K225 and E265 are critical residues for enzyme
function (Figure 3). Figure 4, a superposition of modeled hTYW2
with the crystal structures of its archaeal homolog Pyrococcus
horikoshii TYW2 (PDB-ID: 3K6R and 3A25, free protein and
bound to AdoMet respectively) conveys how residues K225 and
E265 interact with the acp donor AdoMet. E265 H-bonds with the
O2* and O3* of the ribose moiety, and K225 H-bonds with the
terminal oxygen of AdoMet.
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Phe Contained Fully Modified yW
Base
Since hTYW2 plays a role in the formation of yW, it was of
interest to investigate whether the overexpression of hTYW2
observed in human breast tumors affected tRNA
Phe in mouse
mammary tumor tissues. Eight individual tumor samples were
obtained from three different types of transgenic mouse mammary
tumor models, and tested for Tyw2 expression. Each tumor
showed increased Tyw2 expression (Figure S3). The mouse
mammary tumor model C3(1)/Tag [8] was selected because these
tumors showed an average .20 fold increase in Tyw2 gene
expression (Figure 5A) as compared to the normal mammary
tissue. The tumor histology was consistent with adenocarcinomas
(Figure 5B) [8,23]. To analyze the status of the yW base, total
tRNA was extracted from each type of tissue and aminoacylated
with [
3H]phenylalanine and fractionated using reverse phase
column chromatography (Figure 5D); the tumor analyzed here
showed 31 fold higher expression of Tyw2 compared to normal
tissue. An internal control (calf liver [
14C] tRNA
Phe) was included
in each experiment. The tRNA
Phe in both the normal mouse
mammary tissue (top panel), and the tumor tissue (bottom panel)
contained the fully modified wybutosine base. No quantitative
differences in the levels of tRNA
Phe were observed in these tissues
(Figure 5C), nor were there differences in many of the other
modified bases found in tRNA
Phe (data not shown). Thus, the yW
base modification and expression level of tRNA
Phe appeared
unaffected in mouse mammary tumors.
Discussion
We have established that human TYW2 encodes the enzyme
that is required for the posttranscriptional modification of the base
G to yW in tRNA
Phe (Figure 1). The human TYW2 gene could
substitute for its yeast counterpart in providing the enzyme needed
for the catalysis of the third step in the conversion of G37 to yW,
and thus indicating that it plays a similar role in the post-
transcriptional modification of tRNA
Phe in humans. Even though
a large number of post-transcriptional base modifications in
tRNAs have been well characterized, including those from
mammalian tissues, the enzymes that catalyze many of these
modifications are yet unclear, particularly in human or other
mammalian tissues. yW modification is the most complex
modification in tRNA, and an enzyme component of this pathway
in humans has now been characterized.
Earlier, we reported amplification and overexpression of
TYW2 in breast cancer and now we have found that it catalyzes
a step in the modification of G(37) to yW base in tRNA
Phe.
Though the importance of this enzymatic function in tumori-
genesis is not immediately apparent, it was of interest to note
that over 30 years ago tRNA
Phe from mouse neuroblastoma was
shown to be undermodified where the yW base is replaced with
methyl-1-guanosine [5]. The undermodification of the yW base
in tRNA
Phe allowed for retroviral –1 frameshifting during
translation in mammalian cells [6] and recently, using Xenopus
Figure 2. Structure-guided alignment of hTYW2 protein with
its homologs. The alignment shows 18 sequences from the Swiss-Prot
(reviewed, manually annotated) subset of the UniProtKB database
(www.uniprot.org). The alignment of all 49 sequences in the UniProtKB
database, both reviewed (Swiss-Prot) and un-reviewed (TrEMBL)
sequences are presented as Figure S2. The alignment was created
using the Cn3d tool. The color of the residues reflect the level of
conservation with highly conserved residues in red to not conserved
residues in blue, and the residues in smaller letters indicate regions of
no conservation. This alignment shows only the transferase domain
corresponding to residues 118–336 of hTYW2. The sequences are
labeled using UniProtKB accessions. The boxes around the positions of
five residues in TYW2 HUMAN (K225, Y242, F248, E265 and D293) are to
indicate that they were chosen for mutagenesis studies. The circles
indicate the nine residues in TYW2 PYRHO that were analyzed by
mutagenesis, and those resulting in the severe inactivation of the
enzyme activity (.90%) are with filled circles (from Umitsu et al Proc
Natl Acad Sci U S A 106: 15616–15621). PYRHO: Pyrococcus horikoshii;
METJA: Methanocaldococcus jannaschii; ARATH: Arabidopsis thaliana;
BOVIN: Bos taurus; DANRE: Danio rerio; MACFA: Macaca fascicularis;
METJA: Methanocaldococcus jannaschii; MOUSE: Mus musculus; RAT:
Rattus norvegicus; YEAST: Saccharomyces cerevisiae; SCHPO: Schizosac-
charomyces pombe; CANAL: Candida albicans; YARLI: Yarrowia lipolytica
CANAW: Candida albicans; CRYNJ: Cryptococcus neoformans.
doi:10.1371/journal.pone.0039297.g002
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39297Figure 3. Mutagenesis of hTYW2 and evaluation of its effect on its enzymatic function in yW biosynthesis. Mutants, K225A, Y242A,
F248A, E265A, and D293A were introduced into the hTYW2 gene by oligo-directed mutagenesis. These mutant protein expression constructs in the
pYES2 vector were used to transform the yeast TYW2 deletion strain (DTYW2). All the mutant constructs expressed the TYW2 protein (not shown). LC/
MS analysis of nuclease P1 digested tRNA-Phe obtained from the deletion strain DTYW2 transformed with wild type (top left) and the five mutant
hTYW2 constructs in pYES2. For each transformant, the panels show UV at 254 nm (top), and mass chromatograms detecting MH+ (m/z838) of yWpA
(middle), and MH+ (m/z 651) of [yW-187]pA (bottom) respectively.
doi:10.1371/journal.pone.0039297.g003
Figure 4. Superposition of modeled hTYW2 with the structure its archaeal homolog. A) Superposition of the modeled hTYW2 (in beige)
with the crystal structures of Pyrococcus horikoshii TYW2 in the AdoMet bound (PDB-ID:3A25, in green) and unbound (PDB-ID:3K6R, in cyan) forms is
shown. The figure was created using PyMOL visualization software (www.pymol.org). The strands are displayed as arrows. The AdoMet is shown as
a stick model colored in pink with nitrogen atoms in dark blue and oxygen atoms in red. The five amino acid residues in the AdoMet binding pocket
of hTYW2 that were chosen for mutagenesis are labeled, and the H-bonds formed by these residues with AdoMet are shown in yellow dashed lines.
B) A view of the AdoMet binding pocket with only AdoMet and the residues chosen for mutagenesis. AdoMet is shown as a stick with the atoms
labeled. H-bonding interaction of the residues with AdoMet are indicated by dashed-lines: E265 with the O2* and O3* of the ribose moiety, D293 with
N6 of the Adenine ring, and K225 with the terminal oxygen of AdoMet.
doi:10.1371/journal.pone.0039297.g004
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tRNA
Phe not only enhances but is required for frameshifting
[24]. Therefore, we determined whether overexpression of the
hTYW2 disrupted the wybutosine pathway in the mammary
tumor cells. We found that mouse mammary tumor models
overexpressed Tyw2, but the tumor tissue contained the fully
Figure 5. tRNA
Phe from normal and tumor mammary tissue. Mammary tumor tissue was obtained from mice heterozygous for the C3 (1)/
SV40-T/t-antigen [C3 (1)/Tag] transgene in the FVB/N background. Expression of Tyw2, tumor histology, and quantitation of tRNA
Phe are described in
A-C. (A) Tyw2 expression in three mouse mammary tumor measured by RT-qPCR relative to ß2M. (B) Histology of paraffin-embedded C3(1)/Tag
mouse mammary tumor showing adenocarcinoma. (C) Northern blot analysis of tRNA
Phe from C3(1)/Tag mouse mammary tumors, normal mouse
mammary tissue from the same strain(FVB/N), and the calf liver control. The probe, Ser, refers to hybridization with a control probe for tRNA
Ser1 [15].
(D) Elution profile from a RPC-5 column of Phe-tRNA
Phe from normal and tumor tissue. Isolation of tRNA, aminoacylation, and chromatography are as
described in Materials and Methods. The profiles of [
3H]-Phe tRNA from normal (upper panel) or tumor (lower panel) mouse mammary tissues are
shown. [
14C]-Phe tRNA from calf liver is included as an internal control in both the panels. A peak (around fraction 50) represents the tRNA
Phe with the
fully modified yW base, and this is present in both the tRNAs from calf liver and the normal mouse mammary tissue (upper panel) and similarly from
the tumor tissue (lower panel).
doi:10.1371/journal.pone.0039297.g005
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the levels of tRNA
Phe (Figure 5).
Abnormalities in the modified bases in tRNAs have been
described in tumors [25], implying the critical roles of modifying
enzymes in cancer. An increase in the number of dihydrouridine
(D) base in tRNA
Phe from tumors was reported in 1978 [25]. Over
three decades later, dihydrouridine synthase (hDUS) was found to
be overexpressed in lung cancer, and its expression levels
correlated with the aggressiveness of the tumors and, thus, the
patients’ survival [26]. The tRNA methyltransferase, Trm9, was
linked to the regulation of DNA damage response proteins in yeast
[27]. Trm9 is required for the posttranscriptional modification of
uridine, the 34
th base at the wobble position of the anticodon in
tRNA
Arg. In that study, deletion of Trm9 and the associated
failure in modification resulted in tRNA
Arg being ineffective when
reading the codons enriched in certain key DNA damage response
proteins, decreasing the efficiency of their translation [27].
Interestingly, the human homolog of Trm9 is located on
chromosome 8 at 8p22, which is an oft deleted region in
colorectal cancer [28], and microcell transfer studies implicate that
8p22 may harbor a putative tumor suppressor [29]. Mutations in
Dyskerin (DKC1), the human homolog of an rRNA modifying
pseudouridine synthase, leads to dyskeratosis congenita, a pre-
mature aging syndrome with progressive bone marrow failure
syndrome with predisposition to malignancy [30]. However, no
correlation has yet been made to the rRNA modification and the
inactivation of DKC1.
The tRNA modification enzymes described above, via their
ability to alter modifications in tRNAs and translational regula-
tion, play a key role in cancer or cell biology in general. However,
we conclude that overexpression of hTYW2 in mammary cancer
may not adversely affect the yW modification. It is possible that
this overexpression may adversely affect another biological
function that is mediated by this enzyme activity. Alternatively,
human TYW2 may have a yet unknown additional function that
may have a role in tumorigenesis. In yeast, TYW2 was found to
interact with SUP35 protein [31]. The mammalian homolog of
the yeast SUP35 is a cell cycle protein, eRF3/GSTP1. It is
tempting to speculate that further exploration of the TYW2
interacting proteins in mammalian cells might provide clues to its
role in tumorigenesis. Our previous report on the amplification
and overexpression of this gene in breast cancer is the only report
on mammalian TYW2. This was apparent when we performed
network reconstruction (protein-protein interactions) using Meta-
Core (GeneGo, Inc, St. Joseph, MI) in an effort to understand the
pathways TYW2 is involved with (data not shown). However, from
MetaCore analysis it appears that TYW2 is a target of
transcriptional regulation based on chromatin immunoprecipita-
tion studies for proteins cyclinD1 [32], ESR1 [33], and HNF4-
a and HNF6 [34]. Confirming and extending these observations
as to whether these interactions result in altered expression of
TYW2 might open up avenues to explore biological consequence
of overexpression of TYW2.
Based on structure-guided sequence alignment of hTYW2 with
its homologs, we chose to evaluate the importance of five amino
acids by site-directed mutagenesis. Two of the five mutants,
K225A and E265A, lacked enzyme activity, showing that K225
and E265 are critical residues for the acp transferase activity of
hTYW2 enzyme. A comparison of the positions of these mutations
on the structure shows that the glutamic acid (E265) residue forms
a H-bond with the ribose moiety, which is involved in catalysis in
the known methyltransferases [35]. The lysine (K225) residue
forms H-bond with the terminal oxygen, and is positioned close to
the propyl group being transferred in this reaction (Figure 1 and
4). Thus, for transfer of the acp group as opposed to a methyl
group, the residues that are important are those that hydrogen
bond with the terminal oxygen, and O2* and O3* of the ribose
moiety. This is consistent with the mutagenesis of the correspond-
ing residues in archaeal TYW2, E155A and R116A, which
resulted in nearly eliminating the enzyme activity [20]. Structural
and functional conservation of human TYW2 with its evolution-
arily distant neighbor archaeal TYW2 is clearly apparent from
modeling and mutagenesis studies.
Supporting Information
Figure S1 Single-Linkage clustering tree. The tree was
generated using CDTree tool (http://www.ncbi.nlm.nih.gov/
Structure/cdtree/cdtree.shtml). There are three clusters corre-
sponding to archaea, mammals and fungi. The PYRHO (archaea),
HUMAN and YEAST TYW2 sequences are indicated by a star.
The three clusters belong to three protein homeomorphic families
(homeomorphic here indicates that the proteins that belong to
a family have similar lengths and domain architectures).
Representative sequences from these families, PIRSF006525
(archaea), PIRSF038667 (mammals) and PIRSF038972 (fungi)
were used. Single-linkage clustering creates protein clusters with
the restriction that the sequence of a protein recruited to a given
cluster aligns with the recruiting sequence over at least 85%
percent of both sequences. Initially, the aligned sequences must
share 100% identity. Thereafter, the identity criterion is iteratively
decremented by one and clustering is repeated. Trees are
produced by examination of clusters at each iteration. Since this
is a clustering tree, no bootstrap values are provided. Six sequences
represent the PDB IDs, and are derived from crystal structures of
Pyrococcus horikoshii TYW2 (PhTYW2) and Methanocaldococcus
jannaschii TRM5 (MjTRM5): 3K6R A (PhTYW2), 3A25 A
(PhTYW2 with AdoMet), 2YX1 A (MjTRM5), 2YX1 B
(MjTRM5), 2ZZM A (MjTRM5 with tRNA
Leu), 2ZZN A
(MjTRM5 with tRNA
Cys). Other sequences are labeled using
UniProtKB accessions (www.uniprot.org), and the complete
names of the species are provided in Table S1.
(TIF)
Figure S2 Structure-guided alignment of hTYW2 pro-
tein families and their homologs. The alignment shows all
representative sequences that belong to three families as classified
by PIR (pir.georgetown.edu) named PIRSFs. The TYW2
members belong to PIRSF006525(archaea), PIRSF038972(fungi)
and PIRSF038667(mammals). The alignment was created using
the Cn3d tool. The residues are colored based on the level of
conservation with highly conserved residues in red to not
conserved residues in blue. The residues in lower case letters
indicate regions of no conservation. This alignment includes the
transferase domain (amino acids 118–336) and extends to the c-
terminus (amino acid 448) of hTYW2. The positions of the five
residues in TYW2 HUMAN chosen for carrying out mutagenesis
are shadowed in gray (K225, Y242, F248, E265 and D293). The
residues in TYW2 PYRHO that were analyzed by mutagenesis
(taken from Umitsu et al Proc Natl Acad Sci U S A 106: 15616–
15621) are indicated by circles on top, and those resulting in the
severe inactivation of the enzyme activity (.90%) are shown with
the filled circles (taken from Umitsu et al Proc Natl Acad Sci U S A
106: 15616–15621). The sequences are labeled using UniprotKB
accessions (www.uniprot.org), and the complete names of the
species are provided in Table S1.
(TIF)
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RNA from multiple mouse mammary tumor tissues.
RT-qPCR was performed on RNA from eight individual tumor
samples. The number of individual tumors and the mammary
tumor model they were derived from is indicated in the X-axis.
These tumors are from three different mouse mammary tumor
models generated by transgenic expression of SV40 -T/t antigen
[C3(1)/Tag], Polyoma middle T oncogene [MMTV-PymT] and
Her2/neu oncogene [MMTV-Her2/neu]. C3(1)/Tag tumors are
from different lineages than those presented in Figure 5. The fold
change in Tyw2 gene expression (relative to that from ‘‘Normal’’
FVB/N strain) is shown in the Y-axis. The expression of
housekeeping gene b2M was used as an internal control. Each
bar represents the mean and SD of measurements in triplicates.
(TIF)
Table S1 Complete names of the organisms. The names
of the organisms in the UniProt Accessions used to generate
Figures S1 and S2 are expanded to provide complete names.
(XLSX)
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